During 2018 Q2 the big money sentiment decreased to 1.69. That’s change of 0.63, from 2018Q1’s 2.32. 19 investors sold all, 20 reduced holdings as ECYT ratio fall. 16 increased stakes while 50 funds bought stakes. Funds hold 47.24 million shares thus 13.70% more from 2018Q1’s 41.55 million shares. Ubs Asset Mngmt Americas invested in 0% or 29,500 shs. Royal National Bank & Trust Of Canada holds 7,050 shs or 0% of its capital. Manufacturers Life The accumulated 0% or 48,476 shs. Rhumbline Advisers, a Massachusetts-based fund reported 62,865 shs. Federated Invsts Pa has 233 shs. Wellington Management Grp Inc Llp has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Venbio Select Advisor Limited Company invested 3.03% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Moreover, Bancorporation Of Montreal Can has 0% invested in Endocyte, Inc. (NASDAQ:ECYT). Financial Architects stated it has 0% in Endocyte, Inc. (NASDAQ:ECYT). Gemmer Asset Mgmt Limited Liability Company has 1,500 shs. Atika Management Lc holds 0.78% or 295,000 shs. 107,620 were reported by Sanctuary Wealth Advsr Ltd Liability Co. Wells Fargo & Mn stated it has 113,770 shs or 0% of all its holdings. Pnc Grp holds 500 shs. Proshare Advsrs Lc holds 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT) for 37,769 shs.
ECYT registered $729,997 net activity with 0 buys and 5 selling transactions since June 12, 2018. The insider Armour Alison A. sold $22,589. Leamon Christopher P also sold $347,323 worth of Endocyte, Inc. (NASDAQ:ECYT) on Tuesday, August 28.
Ra Capital Management Llc upped its stake by 45.55% in Endocyte Inc (ECYT), according to 2018Q2 SEC filling. The company’s stock popped up 31.32% while Ra Capital Management Llc bought 1.77M shares. The health care company announced $77.97M value for the 2018Q2. Now the hedge fund is holding 5.65 million shares, compared to the 3.88M from the previous quarter. For a total of shares it reduced its holding in by shares in the quarter, and has cut its stake in .
For more Endocyte, Inc. (NASDAQ:ECYT) news brought out recently go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Novartis To Buy Endocyte In $2.1B Deal” brought out on October 18, 2018, “Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and …” on November 09, 2018, “Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates” with a publish date: October 18, 2018, “Best Performing Stocks YTD 2018” and the last “Endocyte Provides Third Quarter 2018 Financial Results and Operational Update” with publication date: November 07, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.